Women are about the be bombarded with DTC ads for Lybrel:

"So what's a poor company to do?" Houppert writes, adding, "Re-conceptualize menstruation as a disease in need of treatment." She writes, "And what's a poor menstruating woman to do? Get cranky with the prophets who offer to cure us of menstruation; who minimize the complex interplay of hormones and their many roles in our bodies; who gloss over the ...

Read more...

It's can be very different, and Shadowfax writes why you should care.

Many have been calling Exubera a bomb since it was introduced. Now the numbers back it up. I don't know any primary care provider or endocrinologist who is prescribing this:

"Yesterday, Pfizer broke out Exubera sales for the first time, and now we know why it took this long: Exubera only sold $4 million in 2Q. This for a product that has been on the market for ...

Read more...

Sid Schwab with more stories from the trauma room.

Medicaid patients have a tough time finding a physician, due to ridiculously low reimbursements:

For example, Medicaid pays AppaRao Mukkamala, president of the Michigan State Medical Society and a radiologist in Flint, Mich., $20 for a chest X-ray while his costs are $29. "At this point, I have to pay money out of my own pocket to take care of that [Medicaid] patient, and it's only going to get ...

Read more...

Leaving AMA

Physicians have different takes on patients leaving against medical advice. Some would gladly show patients the door. Others would really try to fight to do what's best, like this resident:

"We tried deals and scare tactics, telling him as clearly as we could that he was more likely to die if he left this way," writes Dr. Viviany R. Taqueti. "When he countered with 'that is up ...

Read more...

height="350" width="425">

(via Street Anatomy)

Maria calls it extortion. While reading the piece, I was waiting for the punch line: "Practicing medicine while board-certified: priceless."

Chris Rangel has emerged from his blogging sabbatical with some great stuff about physician-employees and incentives:

But as an incentive the company agreed to pay this local internist PER PATIENT (just like what any self-employed doc gets). This internist was only too happy to comply. He got to the hospital at 4 or 5 am, saw patients until 10 or 11 am, then went to see his office patients until ...

Read more...

The potential case of the year.

Investor's Business Daily with their take:

"Sicko" is bombing - financially and politically. After three weeks in wide release, it has managed to scrape together just $15.8 million in box office receipts. For most documentaries, that would be a notable take. But given the expectations, this is an enormous failure.

Box Office Mojo, which tracks ticket sales, notes that the movie will struggle to match "Bowling for Columbine," Moore's ...

Read more...

The outrage continues as radiologists are excluded from the mix. (via GruntDoc)

Futile care

Another large driver of health care costs comes under scrutiny:

"The biggest problem here is futile treatment," he said. "That's when it's clear after some time that a patient, under normal medical circumstances, is never going to get better.

"People say there could be a million in one chance of recovery, but we can't work that way."

A doctor in Canada suggests offering vaccines in bars to reach young adults.

Gawande on Sicko

In a New Yorker op-ed:

"Sicko" doesn't really offer solutions. Yes, it visits France. But it doesn't discuss the difficulties of reforming a system that encompasses sixteen per cent of the economy. It doesn't investigate the tradeoffs that universal health care will inevitably require. It's an outrage machine.

Sanjay Gupta takes us inside the OR:

Then, the procedure began. You could immediately notice the diseased part of the lung. A healthy lung has a very smooth border. It almost glistens, and it has a reddish look about it.

But Speaker's diseased area had a lot of bumps on it. Other parts of the lung were much darker. It almost looked like some of the cells had ...

Read more...

Dr. Rob connects the two.

Harvard Pilgrim CEO Charlie Baker explains the byzantine world of the Explanation of Benefits.

Competition from generics are hurting Zoloft, Norvasc and Lipitor sales. Torcetrapib was supposed to save them - but now the pipeline looks pretty empty.

From India



(via Running a hospital)

Most Popular